USPTO Examiner ALAM AYAAN A - Art Unit 1611

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18660160COMPOSITIONS OF NITRATES AND METHODS OF USE THEREOFMay 2024November 2025Allow1821NoNo
18649759NICOTINE TABLETApril 2024June 2025Allow1301NoNo
18596096COMPOSITIONS FOR CONTROLLING A PLANT DISEASEMarch 2024October 2025Allow2011NoNo
18526914NOVEL WOUND DRESSING BASED ON CELLULOSE ACETATE FILMS CONTAINING BINARY METAL OXIDE NANOHYBRIDSDecember 2023May 2025Abandon1730NoNo
18506928UV PROTECTANT FORMULATIONSNovember 2023October 2025Abandon2441YesNo
18221957NOVEL WOUND DRESSING BASED ON CELLULOSE ACETATE FILMS CONTAINING BINARY METAL OXIDE NANOHYBRIDSJuly 2023February 2025Abandon1931NoNo
18348891NICOTINE TABLETJuly 2023February 2024Allow800YesNo
18199322COMPOSITIONS OF NITRATES AND METHODS OF USE THEREOFMay 2023October 2025Allow2921YesNo
18032659COMPOSITIONS FOR TREATING INFLAMMATIONS, WOUNDS AND SCARRINGApril 2023January 2026Abandon3301NoNo
18030149THREE-DIMENSIONAL IMPLANTABLE MATRIX WITH REDUCED FOREIGN BODY RESPONSEApril 2023September 2024Allow1721NoNo
18167574METHOD OF PREPARING A DEGRADABLE PRODUCTFebruary 2023January 2026Abandon3550NoNo
18161230IONIZING IRRADIATION STERILIZATION OF BACTERIAL MINICELL-BASED BIOPHARMACEUTICALS AND METHODS OF USEJanuary 2023June 2025Allow2800NoNo
18102666Hemp Essential OilJanuary 2023November 2025Abandon3401NoNo
18146189ANTIBACTERIAL MAGNESIUM HYDROXIDE COMPOSITIONDecember 2022April 2024Allow1510NoNo
17922674ANTIBIOTIC AND ANTI-INFLAMMATORY COMPOSITIONS AND METHODS OF USENovember 2022August 2025Abandon3401NoNo
17995226OXIDATIVE STRESS INHIBITOR AND ANTIOXIDANT AGENTSeptember 2022June 2025Abandon3310NoNo
17905098ANTIMICROBIAL MATERIALAugust 2022July 2025Abandon3401NoNo
17801900SWELLABLE ANTIMICROBIAL FIBREAugust 2022August 2025Abandon3601NoNo
17787128CATHETER DEVICE FOR RELEASING PHARMACEUTICALLY ACTIVE COMPOUNDS OVER AN EXTENDED PERIODJune 2022October 2025Abandon4010NoNo
17744811Antibacterial Glucose-based Composite Nanoparticle and Processing Method and Use thereofMay 2022May 2025Allow3611NoNo
17741853EMOLLIENT EMULSIONMay 2022November 2023Abandon1910YesNo
17772232METHOD OF ADMINISTERING SEABERRRY AND SAW PALMETTO EXTRACTS TO INHIBIT 5a-REDUCTASE ACTIVITYApril 2022May 2025Allow3711NoNo
17694557PERSONAL CARE AEROSOL COMPOSITIONS, METHODS AND DEVICESMarch 2022April 2025Abandon3730NoNo
17648302Modified Nano-Silica Gel for Improving Symptoms Caused by Bacteria and Viruses and Preparation Method and Application ThereofJanuary 2022April 2024Allow2711NoNo
17577935CACTI AND CACTI PARTS FOR COSMETIC TREATMENT OF SKIN AND BALDNESS AND HAIR REGENERATION AND REGROWTHJanuary 2022December 2023Abandon2310NoNo
17573824COMPOSITIONS FOR BEAUTY PRODUCTS AND METHODS OF MAKING SAMEJanuary 2022January 2024Abandon2401NoNo
17619488EXTERNAL COMPOSITION FOR SKIN HAVING ITCHING RELIEVING EFFECTDecember 2021October 2025Abandon4721NoNo
17544672CLEANSERDecember 2021May 2024Abandon2911NoNo
17596067DEAD SEA MINERAL BASED IMPLEMENTATION IN HIGH PERFORMANCE NONWOVEN FABRICSDecember 2021February 2024Abandon2711NoNo
17455359DEVICES AND METHODS FOR REDUCING CYSTINE CRYSTALS IN VIVONovember 2021September 2024Allow3431NoNo
17454673NASAL SEPTUM CARTILAGE COMPOSITIONS AND METHODSNovember 2021September 2025Abandon4611NoNo
17609699EXTRACTION OF CANNABINOIDS FROM BIOMASSNovember 2021July 2025Abandon4411NoNo
17608682AGENT FOR REDUCING MALODOR OF FLATULENCE AND/OR STOOLNovember 2021June 2024Abandon3120NoNo
17453239TOPICAL COMPOSITION FOR CONTROL OF DEMODEXNovember 2021June 2025Abandon4441NoNo
17513800Microstructured Textile with Microencapsulated CompoundsOctober 2021October 2024Abandon3631YesNo
17606925Pharmaceutical Composition Comprising VenetoclaxOctober 2021March 2025Abandon4001NoNo
17504338CLAY MINERAL-BASED TREATMENTS IN PSEUDOMONAS AERUGINOSA INFECTION CONTROLOctober 2021September 2024Abandon3521NoNo
17491005METHODS, COMPOSITIONS AND ARTICLES FOR OLFACTORY-ACTIVE SUBSTANCESSeptember 2021June 2025Abandon4530NoNo
17466455Method of Using Cannabinoids Encapsulated in Phospholipid Carriers for Transmucosal and Transdermal AdministrationSeptember 2021November 2023Abandon2610NoNo
17479122BIOBASED, BIODEGRADABLE COMPOSITE POWDER FOR USE IN COSMETICSSeptember 2021April 2025Allow4341NoNo
17281742ORAL COMPOSITION COMPRISING B-ESCIN AND THE USE THEREOFAugust 2021November 2025Abandon5510NoNo
17429543COMPOSITION FOR PREVENTING OR TREATING TINNITUS COMPRISING VITIS VINIFERA LEAF EXTRACT AS ACTIVE INGREDIENTAugust 2021January 2026Allow5330NoNo
17427868METHOD FOR PRODUCING GELATINOUS COMPOSITIONAugust 2021June 2025Abandon4721YesNo
17423627TITANIUM PHOSPHATE POWDER AND WHITE PIGMENT FOR COSMETIC PREPARATIONSJuly 2021January 2025Abandon4220NoNo
17423705SOLID MICRONIZED MELATONIN COMPOSITIONJuly 2021May 2025Abandon4621NoNo
17423706COMPOSITION FOR PREVENTING OR TREATING PROSTATIC HYPERPLASIA COMPRISING MIXED EXTRACTS OF CURCUMAE RADIX AND SYZYGII FLOSJuly 2021July 2025Allow4820YesNo
17418990PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING MALE SEXUAL DYSFUNCTIONJune 2021August 2024Abandon3810NoNo
17353906GAS MIXTURES CONTAINING LOW CONCENTRATIONS OF XENON AND ARGON PROVIDE NEUROPROTECTION WITHOUT INHIBITING THE CATALYTIC ACTIVITY OF THROMBOLYTIC AGENTSJune 2021August 2023Abandon2610NoNo
17415258CANNABIS COMPOSITIONS AND METHODSJune 2021March 2025Abandon4511NoNo
17348219PHARMACEUTICAL USEJune 2021December 2025Allow5440YesNo
17295535SINGLE-DOSE USE OF A COMPOSITION COMPRISING A PARTICULAR MIXTURE OF GRAPE EXTRACT AND BLUEBERRY EXTRACTMay 2021November 2024Abandon4211NoNo
17321697Moisturizer SheetsMay 2021July 2023Abandon2611NoNo
17293582AGENT FOR PREVENTING AND/OR TREATING NEURODEGENERATIVE DISEASESMay 2021July 2024Abandon3801NoNo
17319076NOVEL ENCAPSULATED COSMETIC COMPOSITIONS AND USES THEREOFMay 2021February 2025Abandon4531NoNo
17318346UV Protectant FormulationsMay 2021January 2025Abandon4441NoNo
17306293HAND CLEANING COMPOSITION WITH TIMED USE DURATIONMay 2021February 2024Abandon3420NoNo
17289575COMPOSITION OF ACTIVE INGREDIENTS, FOR CARE AND SURFACE MODIFICATION OF HUMAN HAIRApril 2021August 2024Abandon3911NoNo
17286253Composition for Neuroprotection, Containing Plant Extract or Fraction as Active IngredientApril 2021March 2025Abandon4720NoNo
17230979PHARMACEUTICAL COMPOSITIONS AND USES THEREOFApril 2021April 2023Allow2410NoNo
17280101COMBINATION OF BACTERIAL BIOLOGICAL CONTROL AGENT AND FATTY ACIDSMarch 2021September 2025Allow5431NoNo
17277341SELF-ASSEMBLING GRAPHENE OXIDE-PROTEIN MATRIXMarch 2021November 2025Allow5621YesNo
17277093COMPOSITIONS AND METHODS FOR TREATING BONE INJURYMarch 2021September 2025Allow5421NoNo
17198783COSMETIC COMPOSITION COMPRISING AMIDE-BASED COMPOUNDMarch 2021July 2023Allow2811NoNo
17269940Cannabis-Infused Product with Extended Cannabinoid Profile User ExperienceFebruary 2021August 2024Abandon4111NoNo
17269921Cannabis-Infused Product with Controlled Cannabinoid Profile User ExperienceFebruary 2021August 2024Abandon4211NoNo
17254347LACTOBACILLUS PLANTARUM FOR SKIN CAREDecember 2020June 2024Allow4221NoNo
17127171BIODEGRADABLE IRON-BASED ALLOY COMPOSITION, MEDICAL IMPLANT APPLYING THE SAME, AND MANUFACTURING METHOD THEREOFDecember 2020April 2025Abandon5241NoNo
17253312COSMETIC COMPOSITION BASED ON JANUS PARTICLESDecember 2020March 2025Allow5141YesNo
17054310BLOCK COPOLYMER-CONTAINING INORGANIC PARTICLE DISPERSION FOR COSMETICSNovember 2020January 2026Abandon6060YesNo
17090954ANTIMICROBIAL FIBER COMPRISING SILVER, FABRIC AND WOUND DRESSING COMPRISING THE ANTIMICROBIAL FIBER, AND METHODS FOR MANUFACTURING THE FIBER, THE FABRIC, AND THE WOUND DRESSINGNovember 2020June 2024Abandon4321NoNo
17049794METHOD FOR MANUFACTURING POROUS INORGANIC PARTICLE AND LIGHT-REFLECTING COMPOSITION COMPRISING POROUS INORGANIC PARTICLEOctober 2020July 2024Allow4531NoNo
17047473COMPOSITIONS INFUSED WITH NICOTINE COMPOUNDS AND METHODS OF USE THEREOFOctober 2020February 2024Abandon4001NoNo
17046976SURFACE, AIR, TEXTILE, PAINT, PLASTIC, SILICONE AND WOOD, POLYETHYLENE; METAL AND DERIVATIVES ANTIMICROBIAL PROPERTIESOctober 2020July 2023Abandon3301NoNo
17043652COSMETICSeptember 2020June 2023Allow3220NoNo
17041699OIL AGENT-CONTAINING SILICONE ELASTOMER PARTICLE AND USE THEREOF IN COSMETIC COMPOSITION, ETC.September 2020July 2024Allow4631YesNo
16975252PACKAGE AND METHOD FOR PRODUCING THE SAMEAugust 2020May 2024Allow4411YesNo
16998655INCENSE MATERIAL AND METHOD OF MANUFACTURE THEREOFAugust 2020July 2023Abandon3511NoNo
16985891LONG-TERM RE-ABSORBABLE SUBCUTANEOUS IMPLANT WITH CONTROLED PRE-CONCENTRATED PHARMACOLOGICALLY ACTIVE POLYMER SUBSTANCE RELEASE FOR TREATING ENDOMETRIOSISAugust 2020August 2023Abandon3650NoYes
16965214COMPOSITION FOR PREVENTING HAIR LOSS AND PROMOTING HAIR GROWTH AND METHOD FOR PREPARING THE SAMEJuly 2020May 2024Abandon4631NoNo
16962791ANTIMICROBIAL PRESERVATIVE COMPOSITIONSJuly 2020July 2025Allow6051YesNo
16908661COMPOSITION FOR BONE DEFECT AND PREPARATION METHOD OF THE SAME AND KIT FOR THE SAMEJune 2020October 2023Allow4030NoNo
16896011LYCOPENE MICRO-CAPSULE POWDER AND PREPARATION METHOD THEREOFJune 2020May 2023Allow3521NoNo
16894851EMOLLIENT EMULSIONJune 2020August 2022Abandon2721YesNo
16894171INJECTABLE MESHJune 2020May 2025Abandon5961YesNo
16766814COMPOSITION FOR TOPICAL SKIN CAREMay 2020July 2023Abandon3731NoNo
16766514ANTI-INFLAMMATORY COMPOSITION COMPRISING GRAPHENE NANO-STRUCTUREMay 2020June 2023Allow3741NoNo
16761270SYNERGISTIC COMPOSITION FOR UNIVERSAL INCREASE OF AGRICULTURAL PRODUCTIONMay 2020March 2023Abandon3411NoNo
16863408System and Method for Disinfecting an Occupied Environment Using Direction Controlled Germicidal RadiationApril 2020March 2023Abandon3511NoNo
16758641PREVENTIVE AND/OR THERAPEUTIC AGENT FOR DEMENTIAApril 2020November 2022Abandon3021NoNo
16835514COMPOUND, COMPOSITION AND METHOD FOR PROTECTING SKIN FROM TEMPERATURE EXTREMESMarch 2020July 2021Abandon1501NoNo
16835351DEODORANT COMPOSITIONSMarch 2020June 2024Allow5060YesNo
16832461RAPID SET GEL CONCENTRATE FOR MEDICAL PRODUCTSMarch 2020November 2022Abandon3121NoNo
16829214LEAVE-ON LIGHT OIL HAIR COMPOSITIONMarch 2020November 2024Allow5671YesNo
16829157Pest-Repellent CompositionsMarch 2020November 2023Abandon4431NoNo
16825301PERSONAL CARE AEROSOL COMPOSITIONS, METHODS AND DEVICESMarch 2020May 2022Abandon2620NoNo
16649541DEVICES AND METHODS FOR REDUCING CYSTINE CRYSTALS IN VIVOMarch 2020March 2022Abandon2411NoNo
16811971Disinfectant Composition Against the Novel Wuhan Corona Virus COVID-19March 2020December 2021Abandon2220NoNo
16810710DIHYDROMYRICETIN NANOPARTICLE FORMULATIONSMarch 2020December 2022Abandon3321NoNo
16806671METHOD OF USING MACROCYCLIC ACTIVATED PEROXIDES FOR MICROBE REDUCTIONMarch 2020January 2022Abandon2220NoNo
16801081SKIN TREATMENTFebruary 2020April 2022Abandon2620NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner ALAM, AYAAN A.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
1
Examiner Affirmed
0
(0.0%)
Examiner Reversed
1
(100.0%)
Reversal Percentile
91.0%
Higher than average

What This Means

With a 100.0% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.

Strategic Value of Filing an Appeal

Total Appeal Filings
7
Allowed After Appeal Filing
3
(42.9%)
Not Allowed After Appeal Filing
4
(57.1%)
Filing Benefit Percentile
70.3%
Higher than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 42.9% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.

Strategic Recommendations

Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.

Examiner ALAM, AYAAN A - Prosecution Strategy Guide

Executive Summary

Examiner ALAM, AYAAN A works in Art Unit 1611 and has examined 120 patent applications in our dataset. With an allowance rate of 32.5%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 38 months.

Allowance Patterns

Examiner ALAM, AYAAN A's allowance rate of 32.5% places them in the 5% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by ALAM, AYAAN A receive 2.57 office actions before reaching final disposition. This places the examiner in the 75% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by ALAM, AYAAN A is 38 months. This places the examiner in the 28% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +43.2% benefit to allowance rate for applications examined by ALAM, AYAAN A. This interview benefit is in the 89% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 16.2% of applications are subsequently allowed. This success rate is in the 13% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 17.4% of cases where such amendments are filed. This entry rate is in the 20% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 0% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 80.0% of appeals filed. This is in the 71% percentile among all examiners. Of these withdrawals, 25.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.

Petition Practice

When applicants file petitions regarding this examiner's actions, 106.7% are granted (fully or in part). This grant rate is in the 94% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 0% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 0% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Plan for RCE after final rejection: This examiner rarely enters after-final amendments. Budget for an RCE in your prosecution strategy if you receive a final rejection.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.